Afrifund
Menu
About Us
Consulting
Our Team
Our Philosophy
Our Group Structure
Our Vision
Our Thesis
News & Insights
Contact Us
Merck says its Covid antiviral treatment less effective than first thought
Full analysis of trial results shows molnupiravir had a risk reduction of 30%